Get started
IMMURON LIMITEDIMMURON LIMITEDIMMURON LIMITED

IMMURON LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

IMC chart


Full chart

IMC upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪15.19 M‬ AUD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.032 AUD
Net income (FY)
‪−6.94 M‬ AUD
Revenue (FY)
‪4.90 M‬ AUD
Shares float
‪196.37 M‬
Beta (1Y)
−0.17

About IMMURON LIMITED


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Steven Lydeamore
Website
immuron.com
Headquarters
Blackburn North
Founded
1994
ISIN
AU000000IMC7
FIGI
BBG000C6G8P0
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IMC news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as IMC.

Frequently Asked Questions


The current price of IMC is 0.065 AUD — it has increased by 4.84% in the past 24 hours. Watch IMMURON LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange IMMURON LIMITED stocks are traded under the ticker IMC.
IMC stock hasn't changed in a week, the month change is a −7.14% fall, over the last year IMMURON LIMITED has showed a −38.10% decrease.
IMC reached its all-time high on Aug 13, 2009 with the price of 3.219 AUD, and its all-time low was 0.050 AUD and was reached on Mar 25, 2020. View more price dynamics on IMC chart.
See other stocks reaching their highest and lowest prices.
IMC stock is 4.69% volatile and has beta coefficient of −0.17. Track IMMURON LIMITED stock price on the chart and check out the list of the most volatile stocks — is IMMURON LIMITED there?
Today IMMURON LIMITED has the market capitalization of ‪15.19 M‬, it has decreased by −4.48% over the last week.
Yes, you can track IMMURON LIMITED financials in yearly and quarterly reports right on TradingView.
IMMURON LIMITED is going to release the next earnings report on Aug 29, 2025. Keep track of upcoming events with our Earnings Calendar.
IMC earnings for the last half-year are −0.011 AUD per share, whereas the estimation was −0.0005 AUD, resulting in a ‪−2.08 K‬% surprise. The estimated earnings for the next half-year are −0.0005 AUD per share. See more details about IMMURON LIMITED earnings.
IMMURON LIMITED revenue for the last half-year amounts to ‪3.99 M‬ AUD, despite the estimated figure of ‪2.50 M‬ AUD. In the next half-year revenue is expected to reach ‪3.00 M‬ AUD.
IMC net income for the last half-year is ‪−2.49 M‬ AUD, while the previous report showed ‪−4.86 M‬ AUD of net income which accounts for 48.83% change. Track more IMMURON LIMITED financial stats to get the full picture.
No, IMC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMURON LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMURON LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMURON LIMITED stock shows the sell signal. See more of IMMURON LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.